Benefit risk assessment and update on the use of docetaxel in the management of breast cancer
Authors:
Open Access
- 1 October 2013
- journal article
- review article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. 5, 357-65
Abstract
Peer reviewed article authored by (Alken S, Kelly CM). Read article or submit your manuscript for publishing.Keywords
This publication has 42 references indexed in Scilit:
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- Adjuvant Chemotherapy in Early-Stage Breast Cancer: What, When, and for Whom?Surgical Oncology Clinics of North America, 2010
- 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineJournal of Clinical Oncology, 2006
- Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 1999
- A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTCAnnals of Oncology, 1996
- Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.Journal of Clinical Oncology, 1995
- Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part IAnti-Cancer Drugs, 1995
- Relationships between the structure of taxol analogs and their antimitotic activityJournal of Medicinal Chemistry, 1991
- A GOMPERTZIAN MODEL OF HUMAN-BREAST CANCER GROWTH1988